Tyra Biosciences Inc.
upsized its planned initial public offering on Tuesday to 9 million share from an earlier plan to offer 6.7 million. The company would raise $144 million at the top of that range at a valuation of $626 million. The biotech’s leading product candidate is a treatment for bladder cancer. It has applied to list on Nasdaq under the symbol “TYRA.” BofA Securities, Jefferies and Cowen are underwriting the deal. Proceeds will be used to fund clinical development, as sell as for potential acquisitions of businesses, technologies, products or assets.